Kadmon is a US biopharmaceutical company (NYSE: KDMN) developing innovative products for significant unmet medical needs. Product pipeline is focused on inflammatory and fibrotic diseases as well as immuno-oncology. Its lead product candidate KD025 has been granted Breakthrough Therapy Designation for the treatment of chronic graft-versus-host disease (cGVHD) after two or more lines of systemic therapy. In November 2019, Kadmon reported positive interim results for KD025 registration study for the treatment of cGVHD and the Company plans to submit NDA to the US FDA in the second half of 2020.

In November 2019, Kadmon and BioNova established a strategic partnership to develop and commercialize KD025 for the treatment of graft-versus-host disease (GVHD) in China.

Founded in 2007, PharmaResources is a leading Contract Research Organization (CRO) based in Shanghai China, specializing in small molecule R&D and manufacture. PharmaResources have built a team with an ingrained culture of supporting clients, implemented clearly articulated program management processes that together enable and fully support open, constructive yet highly confidential communication of data, analyses and ideas with clients. PharmaResources service clients in biotech, start-ups, pharmaceuticals, and generic suppliers in the US, Europe and Asia, and have contributed to the discovery of multiple first-in-class compounds that have been approved by the US FDA.

In January 2020, BioNova and PharmaResources established a research and discover collaboration for the discovery of small molecules targeting two targets selected by BioNova for the treatment of hematologic malignancies. The collaboration may be expanded to other targets based on mutual agreements.

Carna Biosciences Inc. (JASDAQ: 4572) is a biopharmaceutical company focused on the discovery and development of kinase inhibitor drugs to treat serious unmet medical needs in oncology, autoimmune and neurological diseases by inhibiting kinases that are important drivers for those diseases. Carna Biosciences was founded in Kobe, Japan, in 2003 as a spinoff of Japan Organon (Nippon Organon KK). Carna’s initial focus was to develop an extensive number of state-of-the-art, highest quality reagents for kinase drug discovery, and has since established a leading drug discovery program with a significant collection of proprietary chemical libraries.

In March 2020, Carna Biosciences and BioNova established a strategic partnership to develop and commercialize AS-1763, a novel next-generation non-covalent Bruton's tyrosine kinase (BTK) inhibitor for the Greater China territory.

Ardeagen is leveraging over 30 years of biologics drug development experience of its founder, Morris Z. Rosenberg.  Dr. Rosenberg has held positions at Biogen, Eli Lilly, Seattle Genetics, and at Immunomedics. During his tenure at Seattle Genetics, Dr. Rosenberg helped develop one of the world’s leading antibody drug conjugate platforms and played a key role in the launch of Adcetris for Hodgkin Lymphoma and ALCL.  At Immunomedics, he played a played a pivotal role in the approval and launch of Trodelvy for Triple Negative Breast cancer.

WuXi STA, a subsidiary of WuXi AppTec, is a leading pharmaceutical development and manufacturing capability and technology platform company serving the life sciences industry, with global operations. As a premier Contract Development and Manufacturing Organization (CDMO), WuXi STA offers our worldwide partners efficient, flexible and high-quality solutions for integrated CMC (Chemical, Manufacturing, and Control) from preclinical to commercial.

Insilico Medicine, an end-to-end artificial intelligence-driven drug discovery company, is developing artificial intelligence platforms（www.insilico.com/platform/）that utilize deep generative models, reinforcement learning, transformer, and other modern machine learning techniques for novel target discovery and generation of novel molecular structures with desired properties. It is developing breakthrough solutions for the discovery and development of innovative drugs for cancer, fibrosis, infectious diseases, autoimmune diseases, and aging-related diseases. Since its inception, the company raised over $300 million from the reputable financial, biotechnology, and information technology investors.

Sutro Biopharma, Inc., located in South San Francisco, is a clinical-stage drug discovery, development, and manufacturing company. Using precise protein engineering and rational design, Sutro is advancing next-generation oncology therapeutics. Sutro’s proprietary and integrated cell-free protein synthesis platform XpressCF® and site-specific conjugation platform XpressCF+™ led to the discovery of STRO-001 and STRO-002, Sutro’s first two internally-developed ADCs.The platform allows it to accelerate discovery and development of potential first-in-class and best-in-class molecules through rapid and systematic evaluation of protein structure-activity relationships to create optimized homogeneous product candidates. In addition to developing its own oncology pipeline, Sutro is collaborating with select pharmaceutical and biotech companies to discover and develop novel, next-generation therapeutics.

On 12 October 2021, Sutro and BioNova jointly announced an option agreement for BioNova to develop and commercialize STRO-001, a CD74-targeting Antibody-Drug Conjugate (ADC), for patients with hematologic cancers, in Greater China, including mainland China, Hong Kong, Macau and Taiwan.